Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2019 Earnings Conference Call May 13, 2019 8:30 AM ET Company Participants Alicia Grande – Chief Financial Officer Pat McEnany – Chairman and Chief Executive Officer Dan Brennan – Chief Commercial Officer Steve Miller – Chief Operating Officer and Chief Scientific Officer Conference Call Participants Charles Duncan – Cantor Fitzgerald Joe Catanzaro – Piper Jaffray Edward Nash – SunTrust Robinson Humphrey Leland Gershell – Oppenheimer and Company Operator Greet ...

Table of Contents Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 CATALYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 76-0837053 (State or other ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------------|-------|-------|-------|---------------------------------------------------|-------|--------|-----------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Catalyst Oppenheimer 29 Healthcare Conference | th | Annual | Pharmaceuticals | | | | | | | | March 20, 2019 | | | | | | | | | | | | | | | | | | Confidential | | | | | | | | | Safe Harbor 2 Confidential This presentation contains forward-looking stat ...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2018 Results Conference Call March 19, 2019 8:30 AM ET Company Participants Ali Grande - CFO Pat McEnany - Chairman and CEO Dr. Steve Miller - COO and Chief Scientific Officer Dan Brennan - Chief Commercial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Joe Catanzaro - Piper Jaffray Yun Zhong - SunTrust Robinson Humphrey Operator Greetings and welcome to the Catalyst Pharmaceuticals Fourth Quarter and Year-End 2018 Financial Results Ca ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-33057 Delaware 76-0837053 (State of jurisdiction of incorporation or organization)(IRS Employer Identification No.) 355 Alhambra Circle, Suite 1250 Cora ...